Welcome to our dedicated page for Adverum Biotech SEC filings (Ticker: ADVM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ADVM SEC filings page provides access to the historical regulatory record of Adverum Biotechnologies, Inc., a clinical-stage gene therapy company that focused on ocular diseases such as wet age-related macular degeneration (wet AMD). As a former Nasdaq Capital Market registrant, Adverum filed current reports, financial statements, and transaction documents with the U.S. Securities and Exchange Commission, documenting both its clinical development activities and its corporate evolution, including its acquisition by Eli Lilly and Company.
Among the most informative documents for ADVM are its Form 10-K annual reports and Form 10-Q quarterly reports, which describe the company’s business, risk factors, and progress of its lead gene therapy candidate, ixoberogene soroparvovec (Ixo-vec). Investors and researchers can review these filings to understand how Adverum characterized its intravitreal gene therapy platform, the design of pivotal trials such as the Phase 3 ARTEMIS study in wet AMD, and the regulatory designations obtained for Ixo-vec.
Frequent Form 8-K current reports capture material events. For ADVM, these include the October 24, 2025 8-K describing the Agreement and Plan of Merger with Eli Lilly and Company, and the November 21, 2025 8-K noting completion of target enrollment in the ARTEMIS trial and the termination of a North Carolina lease. Earlier 8-Ks furnish press releases on quarterly financial results and pipeline updates, providing additional context on Adverum’s cash runway, clinical milestones, and strategic reviews.
Users can also examine tender offer and merger-related filings referenced in the 8-Ks, which outline the terms of Lilly’s cash offer plus non-tradable contingent value rights (CVRs) for each ADVM share. These documents explain the milestones tied to potential CVR payments and the conditions required to close the transaction. Together, the ADVM filings form a detailed archive of Adverum Biotechnologies’ regulatory history leading up to and including its acquisition, and AI-powered summaries on this page can help distill key points from lengthy reports such as 10-Ks, 10-Qs, and 8-Ks.
Adverum Biotechnologies, Inc. reported a major ownership change linked to its sale to Eli Lilly. A large Frazier Life Sciences affiliated holder reported the disposition of 4,288,949 shares of Adverum common stock on December 9, 2025, at $3.56 per share, leaving 0 shares beneficially owned after the transaction.
The Form 4 explains that this took place upon consummation of a merger under an Agreement and Plan of Merger dated October 24, 2025 among Adverum, Eli Lilly and Company and its wholly owned subsidiary Tigers Acquisition Corporation, including a related tender offer. Under the offer, each Adverum share held by the reporting person was purchased for $3.56 in cash plus one non‑tradable contingent value right (CVR) that may pay up to an additional $8.91 per CVR in cash if two milestones described in the merger agreement are achieved.
Adverum Biotechnologies, Inc. filed post-effective amendments to three existing shelf registration statements to deregister all securities that were previously registered but remain unsold or unissued.
The company explains that on December 9, 2025, Flying Tigers Acquisition Corporation merged with and into Adverum under an Agreement and Plan of Merger dated October 24, 2025, with Adverum surviving as a wholly owned subsidiary of Eli Lilly and Company. As a result, Adverum has terminated all offerings under these registration statements and, after these amendments, no securities remain registered under them.
Adverum Biotechnologies, Inc. reported the early termination of its lease for facilities at 14 TW Alexander Drive in Durham, North Carolina, and the creation of a related financial obligation. The landlord ended the lease effective November 19, 2025, even though the term had originally been set to run through October 2037. As consideration, Adverum agreed to pay $0.1 million in cash within 30 days of receiving the termination notice and to release a previously escrowed $7.4 million promissory note to the landlord, with a maturity date on the earlier of January 31, 2031 or the company reaching $150 million in annual net revenues or royalties from its lead gene therapy candidate, Ixo-vec, and subject to acceleration upon a change of control. Adverum also disclosed that it has completed target enrollment of 284 patients in its pivotal Phase 3 ARTEMIS trial of Ixo-vec as of November 19, 2025, marking an important clinical development milestone.
Adverum Biotechnologies (ADVM) reported Q3 2025 results and outlined pending acquisition terms with Eli Lilly. The company posted a quarterly net loss of $47.7 million (loss per share $2.03) on operating expenses of $48.0 million as research and development rose to $38.9 million. Year‑to‑date net loss was $143.9 million.
Liquidity tightened: cash and cash equivalents were $26.1 million as of September 30, 2025, and operating cash use for the nine months was $109.7 million. Total assets were $72.4 million versus $179.8 million at year‑end, and stockholders’ equity moved to a $(55.7) million deficit. Management disclosed substantial doubt about the company’s ability to continue as a going concern.
On October 24, 2025, Lilly launched a tender offer to acquire all shares for $3.56 in cash per share plus one CVR worth up to $8.91 upon milestones: up to $1.78 on U.S. approval of Ixo‑vec and up to $7.13 if annual worldwide Ixo‑vec net sales exceed $1.0 billion. The company also entered a secured note with Lilly for up to $65.0 million (SOFR + 10%), with $5.0 million funded on October 28 and $15.0 million on November 7. A $10.0 million August private placement added limited cash. Clinical programs advanced with Phase 3 ARTEMIS screening completed and AQUARIUS planned.
Eli Lilly, through its wholly owned subsidiary Flying Tigers Acquisition Corporation, launched a cash tender offer to acquire all outstanding shares of Adverum Biotechnologies (ADVM). Holders who tender will receive $3.56 per share in cash, plus one non‑tradable contingent value right (CVR) per share that entitles the holder to receive up to an aggregate $8.91 in contingent cash payments upon achievement of specified milestones, all subject to the terms and conditions of the CVR agreement and the Offer to Purchase.
The consideration is payable in cash, without interest and less applicable tax withholding, and the CVR provides potential added payments tied to future milestone achievements.
Adverum Biotechnologies (ADVM) is the target of a planned tender offer by Eli Lilly and Company via its wholly owned subsidiary, Flying Tigers Acquisition Corporation, under an Agreement and Plan of Merger dated October 24, 2025.
The tender offer has not yet commenced. Upon commencement, Lilly and its subsidiary will file tender offer materials on Schedule TO, and Adverum will file a Schedule 14D-9 to provide its position. These documents will be available on the SEC’s website and at Lilly’s investor site, and mailed to stockholders at no charge.
The communication includes forward-looking statements noting uncertainties around closing, potential contingent consideration, and availability of financing under a promissory note. Completion of the acquisition is not guaranteed and remains subject to customary conditions.
Adverum Biotechnologies agreed to be acquired by Eli Lilly via a tender offer and follow-on merger. Holders will receive $3.56 in cash per share plus one non‑tradable CVR with potential milestone payments of up to $8.91 per CVR, subject to specified regulatory and commercial milestones for the Ixo‑vec product.
The offer requires a majority of outstanding shares to be tendered and is followed by a merger under DGCL Section 251(h) without a stockholder vote. The board unanimously approved the deal and recommends stockholders tender. The agreement permits a $4,000,000 termination fee in specified circumstances and includes customary non‑solicitation terms and conditions.
Concurrently, Lilly provided up to $65.0 million in secured financing via a note with scheduled advances ($5.0M on Oct 28; $15.0M on Nov 7; $20.0M on Nov 21; $25.0M on Dec 5), interest at SOFR + 10.0%, maturity on January 22, 2026, a 5.0% prepayment premium, and a first‑priority lien. The filing also details treatment of equity awards, including 1,959,880 PSUs becoming effective, and outlines warrant treatment at closing.
Adverum Biotechnologies, Inc. filed a current report describing updated timelines for its pivotal Phase 3 ARTEMIS trial evaluating Ixo-vec in wet age-related macular degeneration. The company plans to complete screening for the ARTEMIS trial this month and now anticipates full enrollment in the fourth quarter of 2025. It expects to announce topline data from this Phase 3 study in the first quarter of 2027, giving a clear view of when key clinical results may become available. The report also notes that these statements are forward-looking and subject to significant risks and uncertainties, and that additional risk factors are discussed in the company’s periodic SEC reports.
Adverum Biotechnologies received an amended Schedule 13G/A from multiple Frazier Life Sciences entities reporting passive holdings in the company's common stock. Frazier Life Sciences Public Fund, L.P. reported 1,129,057 shares (5.4%). Other Frazier funds listed holdings of 427,500 (2.0%), 129,870 (0.6%), 272,945 (1.3%) and 118,059 (0.6%), based on 20,984,161 shares outstanding as of August 5, 2025. The filing clarifies shared voting and dispositive power among named entities, corrects prior attributions to certain committee members, discloses prefunded warrants held by the funds with exercise limits, and includes a certification that the securities were not acquired to influence control of the issuer.
Adverum reported accelerating clinical investment alongside a sharply widening operating loss and constrained liquidity. The company recorded a net loss of $49.2 million for the quarter and $96.2 million for the six months, compared with $30.5 million and $57.6 million in the prior-year periods. Cash, cash equivalents and short-term investments totaled $44.4 million at June 30, 2025 and the company used $81.5 million of cash in operations in the six months. Management states available funds, including proceeds from an August 2025 private placement, are expected to fund operations into the fourth quarter of 2025 but are insufficient to provide twelve months of liquidity, which raises substantial doubt about the company’s ability to continue as a going concern.
On the clinical front, Adverum is advancing its lead program, Ixo-vec. The company initiated the ARTEMIS Phase 3 trial in February 2025 and plans a second Phase 3 trial (AQUARIUS) subject to funding. LUNA Phase 2 52-week topline results showed meaningful treatment-burden reductions (annualized anti-VEGF injection reductions of 88% at 6E10 and 92% at 2E11 with injection-free rates of 54% and 69%), and OPTIC long-term data show durable responses out to multi-year follow-up. The company holds several regulatory designations for Ixo-vec (FDA Fast Track and RMAT, EMA PRIME, MHRA Innovation Passport).
FAQ
What is the current stock price of Adverum Biotech (ADVM)?
What is the market cap of Adverum Biotech (ADVM)?
